Joseph Group Capital Management Purchases 575 Shares of Medpace Holdings, Inc. (NASDAQ:MEDP)

Joseph Group Capital Management increased its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP) by 18.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,620 shares of the company’s stock after purchasing an additional 575 shares during the quarter. Joseph Group Capital Management’s holdings in Medpace were worth $1,203,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently bought and sold shares of MEDP. Orion Portfolio Solutions LLC increased its stake in shares of Medpace by 347.6% during the fourth quarter. Orion Portfolio Solutions LLC now owns 4,248 shares of the company’s stock valued at $1,411,000 after buying an additional 3,299 shares during the period. New Age Alpha Advisors LLC bought a new stake in Medpace in the fourth quarter valued at $1,886,000. Norges Bank purchased a new position in Medpace during the 4th quarter valued at $69,859,000. WINTON GROUP Ltd raised its holdings in Medpace by 43.0% in the 4th quarter. WINTON GROUP Ltd now owns 3,343 shares of the company’s stock worth $1,111,000 after purchasing an additional 1,006 shares in the last quarter. Finally, Mitsubishi UFJ Trust & Banking Corp lifted its position in shares of Medpace by 40.3% in the 4th quarter. Mitsubishi UFJ Trust & Banking Corp now owns 38,630 shares of the company’s stock worth $12,834,000 after purchasing an additional 11,099 shares during the period. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on the stock. Leerink Partners initiated coverage on shares of Medpace in a research note on Monday, March 24th. They issued a “market perform” rating and a $330.00 price target for the company. Robert W. Baird increased their target price on Medpace from $354.00 to $362.00 and gave the stock a “neutral” rating in a research report on Monday, January 27th. Finally, Leerink Partnrs upgraded Medpace to a “hold” rating in a research report on Monday, March 24th. Nine investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $376.30.

Medpace Trading Down 1.3 %

Medpace stock opened at $312.36 on Friday. Medpace Holdings, Inc. has a 12 month low of $302.01 and a 12 month high of $459.77. The business’s fifty day simple moving average is $335.90 and its two-hundred day simple moving average is $339.15. The company has a market capitalization of $9.52 billion, a price-to-earnings ratio of 24.73, a price-to-earnings-growth ratio of 3.81 and a beta of 1.47.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings data on Monday, February 10th. The company reported $3.67 EPS for the quarter, beating the consensus estimate of $2.96 by $0.71. Medpace had a net margin of 19.17% and a return on equity of 51.48%. On average, equities research analysts predict that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.